medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 2

<< Back Next >>

Rev Invest Clin 2009; 61 (2)

Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overwiew

Macías-Rodríguez RU, Torre A

Language: Spanish
References: 76
Page: 161-172
PDF size: 142.06 Kb.


ABSTRACT

Cryptogenic cirrhosis represents the third cause of cirrhosis in Mexico and comprises the clinical spectrum of NAFLD. Insulin resistance is the main factor in NASH development, as well as genetic and environmental factors. Derangement in insulin signaling pathways, either pre-receptor or post-receptor, causes insulin resistance (IR). The post-receptor dysfunction represents the primary cause of IR and links with metabolic syndrome, mainly diabetes and obesity. Prevailing metabolic moment will establish the IR status. NASH progression causes fibrosis, cirrhosis and hepatocelular carcinoma. Therapy is currently directed at treating components of the metabolic syndrome which may be beneficial for the liver. Through different mechanisms IR originates to fat deposit in liver and subsequently under oxidative stress and pro-inflammatory cytokines and then to inflammatory infiltrate, fibrosis and finally cirrhosis. This review focuses on insulin resistance and the related mechanisms of hepatic damage.


REFERENCES

  1. Secretaría de Salud. Dirección General de Información en Salud. Diez principales causas de mortalidad en hombres y mujeres, por grupos de edad 2007. Disponible en: http:// sinais.salud.gob.mx/mortalidad/index.html

  2. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006.

  3. Bonora E, Targher G, Formentini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2003; 21: 52-8.

  4. Targher G, Bertolini L, Padovani R, Rodella S, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease among Type 2 diabetic patients. Diabetes Care 2007; 37: 917-23.

  5. Méndez-Sánchez N, Sánchez-Castillo CP, Villa AR, Madrigal H, et al. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 66-71.

  6. Chavarría-Arciniega S, López-Alvarenga JC, Uribe-Uribe NO, Herrera-Hernández M, González-Barranco J. Relación entre el diagnóstico morfológico de EHNA (esteatohepatitis no alcohólica) y pruebas de función hepática en un grupo de pacientes con obesidad extrema. Rev Invest Clin 2005; 57: 505-12.

  7. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004; 3: 63-5.

  8. Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16.

  9. Ludwig J, Viaggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.

  10. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

  11. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-33.

  12. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, et al. Etiology of Liver Cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-3.

  13. Lingappa VR (ed.). Liver disease. Pathophysiology of disease: an introduction to clinical medicine. 4th Ed. McGraw-Hill; 2003.

  14. Friedman SL. Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiol Rev 2008; 88: 125-72.

  15. Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LAR, et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005; 17: 837-41.

  16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 16: 1221-31.

  17. American Gastroenterological Association. Medical Position statement: nonalcoholic fatty liver disease. Gastroenterol 2002; 123: 1702-04.

  18. Cortez-Pinto H, De Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006; 44: 197-208.

  19. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-66.

  20. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterol 2002; 122: 1649-57.

  21. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172(7): 899-905.

  22. Rivera CA. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiol 2008; 15:109-14.

  23. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin N Am 2004; 88: 787-835.

  24. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.

  25. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-6.

  26. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin N Am 2007; 91: 1063-77.

  27. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatol 2005; 42: 987-1000.

  28. Gastadelli A, Cusi K, Pettit M, Hardies J, et al. Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. Gastroenterol 2007; 133: 496-506.

  29. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007; 11: 105-17.

  30. Loria P, Lonardo A, Bellentani S, Day CP, et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutrition, Metabolism & Cardiovascular Diseases 2007; 17: 684-98.

  31. Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Inter 2006; 26: 566-71.

  32. Boer M, Voshol PJ, Kuipers F, Havekes LM, et al. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24: 644-9.

  33. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004; 8: 639-71.

  34. Goldberg IJ, Ginsberg HN. Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterol 2006; 130: 1343-6.

  35. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.

  36. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetología 2005; 48: 634-42.

  37. Haynes P, Lianpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis 2004; 8: 535-47.

  38. Reddy JK. Nonalcoholic steatosis and steatohepatitis; Peroxisomal β-oxidation, PPARα, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1333-G1339.

  39. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatol 2003; 38: 999-1007.

  40. Serviddio G, Sastre J, Bellanti F, Viña J, et al. Mitochondrial involvement in non-alcoholic steatohepatitis. Molecular Aspects of Medicine 2008; 29: 22-35.

  41. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiol 2008; 15: 91-101.

  42. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytocines and insulin resistance. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 3-10.

  43. Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med 2001; 226: 997-1002.

  44. Lazar MA. Becoming fat. Genes & Dev 2002; 16: 1-5.

  45. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.

  46. Leclercq IA, Morais ADS, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol 2007; 47: 142-56.

  47. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.

  48. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Inter 2006; 26: 1029-39.

  49. Bataller R, Ginés P, Nicolás JM, Görbig MN, Garcia-Ramallo E, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterol 2000; 118: 1149-56.

  50. Yokohama S, Yoneda M, Haneda M, Okamoto S, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatol 2004; 40: 1222-5.

  51. Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12: 322-6.

  52. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.

  53. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterol 1998; 114: 842-5.

  54. Day CP. From fat to inflammation. Gastroenterol 2006; 130: 207-10.

  55. Edmison J, McCullough AJ. Pathogenesis of Non-alcoholic steatohepatitis: human data. Clin Liv Dis 2007; 11: 75-104.

  56. Varela-Rey M, Embade N, Ariz U, Lu SC, et al. Non-alcoholic steatohepatitis and animal models: understanding the human disease. The International Journal of Biochemistry & Cell Biology 2008 (In Press, doi:10.1016/j.biocel.2008.10.027).

  57. Perlemuter G, Davit-Spraul A, Cosson C, Conti M, et al. Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Inter 2005; 25: 946-53.

  58. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. JAMA 1999; 282: 1659-64.

  59. Chavin KD, Yang SY, Lin HZ, Chatham J, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-700.

  60. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Role of oxidative stress in the progression of non-alcoholic steatosis; Aliment Pharmacol Ther 2005; 22(Suppl. 2): 71-3.

  61. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radical Biology & Medicine 2004; 37: 1499-507.

  62. Novitskiy G, Potter JJ, Wang L, Mezey E. Influences of reactive oxygen species and nitric oxide on hepatic fibrogenesis. Liver Inter 2006; 26: 1248-57.

  63. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochemistry 2007; 40: 776-80.

  64. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-19.

  65. Ramalho RM, Cortez-Pinto H, Castro RE, Solá S, Costa A, et al. Apoptosis and Bcl-2 expression in livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006; 18: 21-9.

  66. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.

  67. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis: Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282: G193-G199.

  68. Marchesini G, Natale S, Manini R, Agostini F. The treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 37-9.

  69. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82: 315-22.

  70. Bouneva I, Kirby DF. Management of nonalcoholic liver disease: weight control. Clin Liver Dis 2004; 8: 693-713.

  71. Angulo P. NAFLD, Obesity, and bariatric surgery. Gastroenterol 2006; 130: 1848-52.

  72. Marchesini G, Brizi M, Biabchi G, Tomassetti S, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.

  73. Neuschwander-Tetri B, Brunt EM, Wehmeir KR, Oliver D, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatol 2003; 38: 1008-17.

  74. Harrison SA, Neuschwander-Tetri BA. Pharmacologic management of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 715-28.

  75. Medina J, Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 2005; 65: 2445-61.

  76. Wilfred NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol 2008; 48: S104-S112.




2020     |     www.medigraphic.com